Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Oct 11 2010ImmunoGen, Inc.

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

“These findings are encouraging in light of the prior treatments these patients have received and the stage of their disease at the time of study entry”

Lorvotuzumab mertansine is designed to target and kill cancer cells that express CD56, a protein. This targeted anticancer compound is a potential treatment for Merkel cell carcinoma (MCC), small-cell lung cancer (SCLC), ovarian cancer, multiple myeloma, and other CD56+ tumors. It is wholly owned by ImmunoGen.

Source:

ImmunoGen, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

DASH diet may lower the risk of cardiovascular disease in breast cancer survivors
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery
New trials show promise for immune checkpoint blockers in early-stage lung cancer
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
Study links air pollution to increased colorectal cancer risk through DNA changes
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases
Breakthrough imaging method enhances precision in prostate cancer treatment
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels